Of the several malaria vaccine vectors that target CSP, the most successful to date is a vaccine formulation that consists of a novel fusion protein between the hepatitis B surface protein (HBsAg) and CSP, and additional adjuvants. This evidence concerns the gene DNAJC5 and malaria.